Health Topics — Endocrine, Reproductive & Limbic
The ECS and Testosterone: What Preclinical Research Shows
CB1 receptors are expressed in Leydig cells — where testosterone is synthesized — and preclinical models show that CB1 activation suppresses testosterone production. What the research has found, the chronic stress pathway that connects these systems, and where the human evidence currently stands.
Testosterone research and cannabinoid research intersect at a point most popular health coverage gets wrong — in both directions. The relationship between cannabinoids and testosterone is not straightforwardly positive or negative. It is context-dependent, mechanistically complex, and substantially less studied in non-psychoactive cannabinoids than most readers assume.
The ECS in Testicular Tissue
The testes express cannabinoid receptors throughout their functional tissue. CB1 is present in Leydig cells — the interstitial cells responsible for testosterone synthesis in response to LH stimulation — and in Sertoli cells, which support and nourish developing sperm cells. CB2 is expressed in mature spermatozoa and in testicular macrophages. Endocannabinoids are produced locally in testicular tissue, suggesting the ECS functions as a local regulatory system within the testes rather than only responding to systemic endocannabinoid signaling.
What Preclinical Models Show — And Their Limitations
Animal model studies using THC and synthetic CB1 agonists consistently document suppression of testosterone production. The mechanisms involve both the direct Leydig cell CB1 pathway described above and indirect suppression through HPG axis disruption — reduced LH from the pituitary reduces the stimulus for Leydig cell testosterone production, independent of direct gonadal CB1 effects.
THC's well-documented testosterone suppression in rodent models has been used to infer that cannabinoids generally suppress testosterone — a generalization that does not hold under scrutiny. CBD and CBG have substantially different receptor profiles from THC. CBD is not a potent CB1 agonist — its primary mechanisms (FAAH inhibition, 5-HT1A agonism, TRPV1 activity) do not engage the Leydig cell CB1 pathway with the same potency as THC or synthetic CB1 agonists. CBG is a partial CB1 agonist — activating the receptor to a submaximal degree, and at the concentrations achieved through oral dosing, its effective CB1 activity at Leydig cells has not been characterized.
The Human Cannabis Literature — What It Does and Doesn't Establish
Multiple studies of heavy cannabis users show lower testosterone levels compared to non-users. These are observational studies of THC-dominant cannabis with the same confounding problems documented in the gut microbiome cannabis literature — cannabis users differ from non-users in diet, sleep, alcohol use, stress patterns, and other testosterone-relevant variables that are difficult to control. The findings are not consistent across studies, and the largest study (NHANES data) found no significant association between cannabis use and testosterone in men after controlling for confounders.
No study has examined CBD or CBG specifically for effects on testosterone in human subjects. Extrapolating THC-based human cannabis findings to non-psychoactive cannabinoids is not scientifically supported.
The Stress-Testosterone Connection
The most clinically relevant pathway connecting cannabinoids and testosterone in men is indirect — through chronic stress and cortisol. Cortisol suppresses testosterone through the same HPG axis mechanisms described in the cortisol article in this pillar: reduced GnRH pulsatility, reduced pituitary LH secretion, and direct gonadal resistance to LH at Leydig cells. Chronic stress is one of the most consistent suppressors of testosterone in men across human observational and experimental research.
If CBD or CBG reduce chronic HPA axis activation through their documented stress-modulating mechanisms, testosterone preservation under stress would be a plausible downstream consequence. This is the same indirect pathway logic applied to women's reproductive function in the cortisol article — plausible, mechanistically grounded, and untested in human testosterone outcome studies. The stress-testosterone pathway is probably more relevant to hemp-derived cannabinoid interactions with male hormonal function than direct gonadal CB1 effects, given the modest CB1 agonist profiles of CBD and CBG relative to THC.
The Honest Evidence Summary
CB1 receptors are expressed in Leydig cells, and preclinical models consistently show that potent CB1 agonists (THC, synthetic agonists) suppress testosterone production through both direct gonadal and indirect HPG mechanisms. CBD and CBG are not potent CB1 agonists and should not be assumed to produce the same effects as THC at testosterone-relevant doses. Heavy cannabis use in humans is associated with lower testosterone in some observational studies, but confounding is substantial and results are inconsistent.
No human study has examined CBD or CBG specifically for testosterone effects. The most plausible cannabinoid-testosterone interaction for hemp-derived compounds is indirect — through stress reduction and preserved HPA-HPG axis function — rather than through direct gonadal CB1 agonism. This remains entirely uninvestigated at the level of testosterone as a measured outcome.
References
- Battista, N., Meccariello, R., Cobellis, G., et al. (2012). The role of endocannabinoids in gonadal function and fertility along the evolutionary axis. Molecular and Cellular Endocrinology, 355(1), 1–14.
- Caro, M.P., Estefania, K., Simón, M., et al. (2023). Cannabidiol: A potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules, 13(1), 19.
- Fronczak, C.M., Kim, E.D., & Barqawi, A.B. (2012). The insults of illicit drug use on male fertility. Journal of Andrology, 33(4), 515–528.
- Gorzalka, B.B., Hill, M.N., & Chang, S.C. (2010). Male–female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. Hormones and Behavior, 58(1), 91–99.
- Kolodny, R.C., Masters, W.H., Kolodner, R.M., & Toro, G. (1974). Depression of plasma testosterone levels after chronic intensive marihuana use. New England Journal of Medicine, 290(16), 872–874.
- Thistle, J.E., Graubard, B.I., Braunlin, M., et al. (2017). Marijuana use and serum testosterone concentrations among US males. Andrology, 5(4), 732–738.
- Whirledge, S., & Cidlowski, J.A. (2010). Glucocorticoids, stress, and fertility. Minerva Endocrinologica, 35(2), 109–125.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.